Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
The Pharma Data
APRIL 27, 2021
Sanofi expects 2021 business EPS ( 1) to grow high single digit (2) at CER, barring unforeseen major adverse events. Neurology and Immunology. Total Neurology and Immunology. In the first-quarter, Neurology and Immunology sales were down 3.4% Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6%
52 
Let's personalize your content